Aktis Oncology (NASDAQ:AKTS) Trading Down 6.6% – Here’s Why

Aktis Oncology (NASDAQ:AKTS) shares fell 6.6% on Monday . The company traded as low as $25.91 and last traded at $26.0390. Approximately 62,182 shares were traded during mid-day trading, a decline of 82% from the average session volume of 344,839 shares. The stock had previously closed at $27.88.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on AKTS shares. Raymond James Financial assumed coverage on Aktis Oncology in a research report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 target price on the stock. William Blair assumed coverage on Aktis Oncology in a research note on Wednesday, April 29th. They set an “outperform” rating for the company. HC Wainwright boosted their price objective on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Finally, Weiss Ratings raised shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.00.

Aktis Oncology Stock Down 9.1%

The firm has a 50-day moving average of $22.75. The company has a market cap of $1.35 billion and a PE ratio of -66.66.

Aktis Oncology (NASDAQ:AKTS) last announced its earnings results on Monday, March 30th. The technology company reported ($18.17) EPS for the quarter. The business had revenue of $1.87 million during the quarter. On average, equities research analysts anticipate that Aktis Oncology will post -1.62 earnings per share for the current year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.